Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Shares Outstanding (Weighted Average) (2016 - 2025)

Spero Therapeutics' Shares Outstanding (Weighted Average) history spans 10 years, with the latest figure at $56.0 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 3.67% year-over-year to $56.0 million; the TTM value through Dec 2025 reached $56.0 million, up 3.67%, while the annual FY2025 figure was $56.0 million, 3.67% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $56.0 million in Q4 2025 per SPRO's latest filing, roughly flat from $55.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $56.0 million in Q2 2025 to a low of $29.4 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $45.5 million, with a median of $52.6 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding (Weighted Average): surged 61.09% in 2023, then grew 1.9% in 2024.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $30.9 million in 2021, then rose by 21.65% to $37.6 million in 2022, then skyrocketed by 40.22% to $52.7 million in 2023, then increased by 2.53% to $54.0 million in 2024, then increased by 3.67% to $56.0 million in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Shares Outstanding (Weighted Average) are $56.0 million (Q4 2025), $55.9 million (Q3 2025), and $56.0 million (Q2 2025).